Published in Cancer Epidemiol Biomarkers Prev on December 01, 2006
Genome-wide association studies of cancer. J Clin Oncol (2010) 1.45
The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol (2013) 1.39
Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer (2015) 0.88
CHEK2*1100delC homozygosity in the Netherlands--prevalence and risk of breast and lung cancer. Eur J Hum Genet (2013) 0.86
CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer. Prostate Cancer (2014) 0.80
Lipid metabolic pathways as lung cancer therapeutic targets: a computational study. Int J Mol Med (2011) 0.77
The cell cycle checkpoint inhibitors in the treatment of leukemias. J Hematol Oncol (2017) 0.75
Rapid Detection Method for the Four Most Common CHEK2 Mutations Based on Melting Profile Analysis. Mol Diagn Ther (2015) 0.75
Germline genetic profiling in prostate cancer: latest developments and potential clinical applications. Future Sci OA (2015) 0.75
Programs for Pedigree Analysis: MENDEL, FISHER, and dGENE. Genet Epidemiol (1988) 13.73
Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst (1999) 8.15
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science (1999) 5.09
CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet (2004) 3.97
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet (1997) 3.68
CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet (2004) 3.03
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet (2002) 3.00
CHK2 kinase--a busy messenger. Nat Rev Mol Cell Biol (2001) 2.68
The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet (2003) 1.93
A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res (2004) 1.60
CHEK2 variants associate with hereditary prostate cancer. Br J Cancer (2003) 1.54
Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med Genet (2003) 1.43
Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet (2005) 1.20
CHEK2 1100delC and colorectal cancer. J Med Genet (2003) 1.12
Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer (2004) 1.01
Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol Oncol (2004) 0.97
Colorectal cancer and the CHEK2 1100delC mutation. Genes Chromosomes Cancer (2005) 0.92
Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome. Hum Mutat (2002) 0.91
CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer (2004) 0.90
Contribution of the CHEK2 1100delC variant to risk of multiple colorectal adenoma and carcinoma. Cancer Lett (2003) 0.87
CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer (2004) 0.86
Germline CHEK2*1100delC mutations in breast cancer patients with multiple primary cancers. J Med Genet (2004) 0.83
Analysis of familial male breast cancer for germline mutations in CHEK2. Cancer Lett (2004) 0.81
Rarity of germline 1100delC mutation in CHK2 in patients with malignant melanoma of the skin. Melanoma Res (2004) 0.80
The CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis. Br J Cancer (2004) 0.77
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
The cancer genome. Nature (2009) 23.13
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet (2004) 14.31
The tuberous sclerosis complex. N Engl J Med (2006) 13.53
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet (2007) 11.62
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
The life history of 21 breast cancers. Cell (2012) 10.59
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Signatures of mutation and selection in the cancer genome. Nature (2010) 9.75
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med (2008) 9.64
COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res (2009) 9.59
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet (2006) 9.17
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet (2002) 8.89
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet (2009) 8.30
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A (2006) 8.24
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet (2006) 7.72
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet (2010) 7.62
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35